Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
- DOI
- 10.1158/1535-7163.mct-21-0273
- Published
- 2021-09-04
- Container
- Molecular Cancer Therapeutics
- Publisher
- American Association for Cancer Research (AACR)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1158/1535-7163.mct-21-0273,
title = {Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers},
author = {Samuel J. Klempner and Johanna C. Bendell and Victoria Meucci Villaflor and Laura LaNiel Tenner and Stacey M. Stein and James B. Rottman and Girish S. Naik and Cynthia A. Sirard and Michael H. Kagey and Marya F. Chaney and John H. Strickler},
year = {2021},
journal = {Molecular Cancer Therapeutics},
doi = {10.1158/1535-7163.mct-21-0273},
url = {https://doi.org/10.1158/1535-7163.mct-21-0273}
}RIS
TY - JOUR TI - Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers AU - Samuel J. Klempner AU - Johanna C. Bendell AU - Victoria Meucci Villaflor AU - Laura LaNiel Tenner AU - Stacey M. Stein AU - James B. Rottman AU - Girish S. Naik AU - Cynthia A. Sirard AU - Michael H. Kagey AU - Marya F. Chaney AU - John H. Strickler PY - 2021 JO - Molecular Cancer Therapeutics DO - 10.1158/1535-7163.mct-21-0273 UR - https://doi.org/10.1158/1535-7163.mct-21-0273 ER -
APA
Klempner, S. J., Bendell, J. C., Villaflor, V. M., Tenner, L. L., Stein, S. M., Rottman, J. B., Naik, G. S., Sirard, C. A., Kagey, M. H., Chaney, M. F., & Strickler, J. H. (2021). Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-21-0273
Source records
- crossref · retrieved 2026-11-08T06:03:48.587Z